Although FGF−21 has beneficial actions, levels are paradoxically elevated in obesity and metabolic disease, often reflecting compensatory up−regulation and “FGF−21 resistance” (66). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.